جستجوی مقالات مرتبط با کلیدواژه « botulinum toxin A » در نشریات گروه « پزشکی »
-
Introduction
Aesthetic applications of botulinum toxin type A (BoNT-A) may lead to some complications, including unwanted muscle paralysis. Moreover, BoNT-A effects may last several months, and there is no medical intervention so far to accelerate muscle function recovery.
Case Report:
A female patient with a movement disorder of the mimic muscles resulting from BoNT-A injections received daily sessions of photobiomodulation therapy (PBMT). A fast improvement in both facial asymmetry and muscle function was noted within a few weeks. After nine weeks, almost complete recovery was achieved.
ConclusionAccording to the current case, PMBT seems to be an effective intervention to accelerate muscle function recovery following BoNT-A use.
Keywords: Botulinum toxin A, Photobiomodulation therapy, Facial muscles} -
Background
We aimed to assess the efficacy of Intraprostatic Onabotulinumtoxin-A (BTA) on the International Prostate Symptom Score (IPSS) and other objective measures of patients with Benign Prostatic Hyperplasia (BPH).
MethodsFifteen patients were included in this study. The drug (BTA; 150 IU) was reconstituted in 20 mL of 0.9% saline before administration to the patients. After providing urethral anesthesia, 20 intraurethral injections were made to lateral lobes of the prostate, 10 injections in each lobe. Follow-up visits were planned 3 and 12 months after the intervention. Pre- and post-interventional IPSS, Prostate-Specific Antigen (PSA), Prostate Volume (PV), Post-Void Residue (PVR), and maximum urinary flow rate (Qmax) compared via paired t-test. Finally, we reviewed the Pubmed database to provide a more precise conclusion.
ResultsThe Mean±SD age of patients was 69±8.24 years, and the mean IPSS score decreased significantly from 24.3±3.3 to 14.6±3.7 (p<0.001) and 16.86±3.06 (p<0.009) on the 3rd and 12th months, respectively. The Mean±SD PSA, PVR, Qmax, and PV were 3.26±1.38, 82.33±35.55, 8.56±1.76, and 47.86±8.93, respectively at baseline. These factors significantly improved to 2.72±1.33 (P<0.000), 71.33±30.55 (p<0.000), 9.5±1.33 (p<0.011), and 42.86± 6.04 (p<0.000), respectively, on the 12th month follow-up.
ConclusionAlthough the overall results support the efficacy of BTA for BPH, the best route of administration, the most effective dose, the optimal number, and the volume of injections need further investigations. The probable placebo effect and underlying medical conditions (e.g., insulin resistance) should be considered as the confounding factors.
Keywords: Benign prostatic hyperplasia, Benign prostatic hypertrophy, Botox, Onabotulinumtoxin-A, Botulinum toxin A} -
IntroductionChronic facial nerve palsy has long been known to negatively affect the quality of life in patients. The present study aimed to investigate the efficacy of Botulinum Toxin A (BTX-A) and neuromuscular retraining therapy (NMRT) in the symmetry of chronic facial palsy.Materials and MethodsTwo groups, namely experimental and control, were considered each consisting of 13 patients. The study population included a total of 15 female subjects. The BTX-A was injected into the synkinetic muscle in the experimental group; nevertheless, the patients in the second group participated in special neuromuscular retraining. The rate of reducing synkinesis and symmetrical improvement was evaluated using the Facial Grading System (FGS) after 4 months of treatment. The independent t-test was performed to compare the two groups.ResultsAccording totheSunnybrook FGS,the mean changes in Sunnybrook scores in the experimental and neuromuscular retraining groups were 3% and 24%, respectively. The comparison of the mean scores of the two groups was statistically significant after the interventions (P=0.033). A variable ratio of statistically significant improvement was observed in synkinesis in both groups following the treatment (P=0.041). In addition, by comparing the synkinesis scores between the two groups, the reduction of synkinesis was observed to be greater in the neuromuscular retraining group (P=0.041) after the treatment.ConclusionsThe findings of the current study indicated that special neuromuscular retraining leads to significant improvement in the FGS score, compared to botulinum toxin therapy alone. Moreover, it was observed that facial symmetry can be treated with special neuromuscular retraining and the patient can overcome synkinesis.Keywords: Botulinum toxin A, Facial nerve palsy, Neuromuscular retraining, Synkinesis}
-
Context
Synkinesis refers to an involuntary movement accompanying a voluntary one that is a consequence of facial paralysis. The cosmetic procedure is used for the management of synkinesis that results in facial symmetry. Botulinum A toxin (BTX-A) has been used for more than two decades for resolving asymmetry and synkinesis. However, the endpoints remain to be further explained. The purpose of this study was to analyze research trends in facial synkinesis and asymmetry after facial nerve palsy (FNP).
Evidence AcquisitionThe databases Medline, PubMed, ScienceDirect, CINHAL, Scopus, and ProQuest were searched for articles published between 1970 and 2017 using the keywords, ‘facial paralysis’, ‘Bell’s palsy’, ‘synkinesis’, and ‘Botulinum A toxin’.
ResultsIn total, 13 eligible articles, cumulatively examining 332 patients, entered the analysis. They were divided into three groups as follows. Eight articles in group I were taken as case series with 181 patients. Two articles in group II compared BTX-A and neuromuscular rehabilitation with 61 patients. Both these groups concluded that BTX-A injection could help reduce synkinesis. In group III, only were three randomized clinical trials retrieved with 90 patients that reported disparate findings.
ConclusionsBTX-A injection cannot yet be proposed as a solution for synkinesis reduction to achieve symmetry and overcome this complication of facial nerve palsy because of the small number of randomized clinical trials available on the subject. Further studies are recommended to be able to make a firm conclusion.
Keywords: Asymmetry, Facial Paralysis, Botulinum Toxin A, Synkinesis} -
Background
Intradetrusor injection of botulinum toxin A (BTX‑A) might serve as a minimally invasive substitute in patients with refractory idiopathic overactive bladder (RIOAB). The aim of this study was to evaluate the clinical outcomes related to two different doses of abo‑BTX‑A (AboBTX‑A) in patients with RIOAB.
Materials and MethodsThis prospective clinical trial was performed on 55 women with RIOAB. After determination of trabeculation grade, 300 (no or mild) or 500 (moderate or severe) unit of AboBTX‑A (Dysport) was intravesicaly injected. Before 1, 3, and 6 months after intervention, lower urinary tract symptoms during 24 h were recorded.
ResultsOf the study population, 62% had severe bladder trabeculation. The mean duration of overactive bladder (OAB) was 1.76 versus 5.85 years, for no or mild versus severe trabeculation, respectively. After injections of 300‑ and 500‑unit dosage, there were 19% and 26% early complications such as urinary retention. There was a statistically significant difference between the two groups in OAB score after 1 month (P < 0.001) and duration of OAB symptoms, over three follow‑up times (P < 0.001). The mean preinjection OAB scores between patients with and without recurrence were statistically significant (29.36 vs. 25.07; P < 0.03). Urinary tract infection as a late complication was distinguished in four patients.
ConclusionIn RIOAB, by adjusted dosage of AboBTX‑A related to the grade of bladder trabeculation, in addition to maintain efficacy, consequent complications might not be affected by dosage and the drug dosage could be increased to nearly 60% with less concern associated to complication.
Keywords: Bladder, botulinum toxin A, idiopathic, trabeculation, women} -
BackgroundMigraine is a common type of headache. Sometimes adequate pain relief is not achieved by conventional treatments. Acupuncture and botulinum toxin-A injection are known as non-pharmacological interventions for this purpose. The aim of this research was to compare the effect of acupuncture with botulinum toxin-A injection and pharmacological treatment in controlling chronic migraine.MethodsThis clinical trial was conducted on patients with chronic migraine in the North of Iran during 2014-2015. Eligible patients were randomly allocated to groups receiving acupuncture (A) or botulinum toxin A (B) and controls (C) by designed quadripartite blocks. All patients were evaluated at baseline, one, two and three months after treatment using visual analogue scale (VAS) score and other parameters. The analysis of data was performed in SPSS software Version 19.ResultsOne hundred fifty patients (48 males and 102 females) completed this study. During the 3- month study, the pain severity significantly diminished in three groups (P=0.0001), with greater reduction in group A (P=0.0001). The number of days per month with migraine, absence from work and the need for medication significantly decreased in three groups at 3 times of evaluation (pConclusionAcupuncture, botulinum toxin-A injection and pharmacological treatment have beneficial effects on chronic migraine; however, acupuncture showed more effectiveness and fewer complicationsKeywords: Migraine, Chronic, Acupuncture, Botulinum Toxin-A, Pain Management}
-
Botulism is one of the most important foodborne diseases and is caused by Clostridium botulinum toxin. The main manifestations are flaccid muscle paralysis and cranial nerve palsies. Botulism is an essential health problem because of its high mortality. The diagnosis of botulism, especially in sporadic cases, is a medical challenge and a high clinical suspicion is necessary for early recognition. So, every physician should be familiar with its signs and symptoms for early detection and treatment. We describe a family with dysphasia and acute paralysis after the ingestion of locally made cheese. The clinical presentations of the 1st patient were similar to myasthenic crisis and she, therefore, received plasma exchange. After the appearance of similar symptoms in the other family members, they were treated with polyvalent botulinum antitoxin and diagnosis was confirmed by toxicology and detection of serotype A botulinum toxin in cheese and stool samples. Uncommon clinical presentations and unusual sources of botulinum toxin should be kept in mind because of the importance of early diagnosis and treatment.Keywords: Botulism, Botulinum toxin A, Cheese}
-
Background
The use of botulinum toxin-A is increasing for aesthetic treatments and new reassuring data have been reported in recent studies. The purpose of this study was to evaluate the complications of botulinum toxin-A (BoTo-A) (NEURONOX) injection to eliminate wrinkles in the upper one-third of the face.
MethodsThe present study was conducted on 235 patients referring to the dermatology clinic of Rasoul Akram hospital in Iran (including 82 men and 153 women with a mean age of 50 years) for the treatment of forehead, frown, and lateral orbital rim wrinkles between 2011 and 2015. The injection level was 35 units of botulinum toxin-A (NEURONOX) for women and 45 for men in the glabella area, and 15 units for women and 20 units for men in the crow’s feet area.
ResultsThe complications of botulinum toxin-A injection among 235 subjects were as follows: 1.3% ptosis (n = 3), 1.7% angioneurotic edema (n = 4), 2.1% vasovagal syncope (n = 5), 3.8% haematoma (n = 9), 1.7% diplopia (n = 4), and 2.1% musculoskeletal pain (n = 5). The satisfaction rate of patients with a complication measured one month after injection indicated that 63.3% (19/30) were satisfied with the injection and 36.7% (11/30) were dissatisfied. The satisfaction rate of patients without a complication showed that 91.7% (188/205) were pleased and 8.3% (17/205) were dissatisfied with the injection.
ConclusionsAccording to the findings of this study, the injection of BoTo-A (NEURONOX) to attenuate glabellar lines and the lateral orbital rim was safe and effective. The complications in this study were not serious and generally were transient and self-limiting
Keywords: Complications, Botulinum Toxin-A, Glabella Ptosis} -
Flushing is a condition with episodic attacks of redness of the skin with a sensation of warmth or burning, this disease causes emotional and functional problems in patients. There is various treatments for this condition; one of them is the use of botulinum toxin-A (BTA). In this prospective pilot study we studied the effect of Botulinum toxin-A (BTA) effect on DLQI of patients with facial flushing, we compared the DLQI before and after treatment. The number of 24 women with facial flushing admitted to the department of dermatology of Hamadan Farshchian Hospital, with the age range of 18 to 60 was enrolled in the study. Patients completed Dermatology Quality of life Index questionnaire before and one month after treatment. In our study 1 unit of BTA was injected intracutaneously per square cm in both sides of cheeks, to a total dose of 30 units per session. All of 24 patients completed the study. The mean age was 37.79±13.13. In all patients, DLQI decreased, and in two months follow up, the mean of DLQI improved from 8.08±1.17 to 4.5±1.21 (P.valueKeywords: Flushing, Botulinum toxin A, Injection}
-
زمینه و هدفاسکار هیپرتروفیک ضایعه ای است که بر اثر ترمیم بیش از حد زخم ایجاد می شود و برای بیماران مبتلا، عوارض زیبایی و گاه عملکردی به جا گذاشته و موجب مشکلات جسمی، روحی و تغییر کیفیت زندگی آنان می شود. امروزه روش های گوناگونی ازجمله جراحی برای درمان این ضایعات به کار می رود اما به دلیل عود مکرر، مشکلات بیمار پابرجا می ماند. در این مطالعه اثر تزریق توکسین بوتولینیوم نوعA در درمان اسکار هیپرتروفیک بررسی شد.
روش اجرا: بیست و یک بیمار مبتلا به اسکار هیپرتروفیک در این کارآزمایی بالینی دوسوکور در سال های 1393 و 1394 مورد بررسی قرار گرفتند. در هر بیمار یک قسمت از ضایعه به صورت تصادفی به عنوان ناحیه ی مداخله و قسمت دیگر ضایعه به عنوان شاهد انتخاب شد. در گروه اول (مداخله)، توکسین بوتولینیوم نوع A (Dysport ساخت کشور انگلستان، شرکت سازنده Ipsen، شرکت واردکننده داریان دارو) با غلظت 200 واحد در میلی لیتر و با دوز 8 واحد به ازای هر سانتی متر مکعب ضایعه و در گروه دوم (شاهد)، با همان حجم نرمال سالین در فواصل یک ماهه تا سه بار تزریق شد. بیماران 9 ماه پس از آخرین تزریق طبق معیارهای ونکوور (Vancouver) بررسی و داده های گردآوری شده تحلیل شدند. در این مطالعه، 0/05>P معنی دار درنظر گرفته شد.یافته ها21 بیمار با میانگین سنی 2/27 سال مطالعه را به پایان رساندند. میانگین شاخص رنگ (pigmentation) در گروه مورد 0/73 کاهش داشت (0/01>P) درحالی که کاهش آن در گروه شاهد معنی دار نبود (0/24=P). میانگین وضعیت عروقی (Vascularity) گروه مورد 0/9 (0/01>P) و در گروه شاهد 0/15 بود (0/15=P). قوام ضایعه در گروه مداخله 0/98 (0/01>P) و در گروه شاهد 0/23 به دست آمد (0/19=P). میانگین تغییرات اندازه یا ارتفاع ضایعه در گروه اول و دوم معنی دار نبود (0/32=P).نتیجه گیریتزریق توکسین بوتولینیوم نوع A در اسکار هیپرتروفیک، نه به عنوان یک روش مستقل بلکه در کنار روش های دیگر درمانی مانند جراحی، می تواند در کنترل و بهبود علائم ناشی از اسکار مفید باشد.کلید واژگان: توکسین بوتولینوم نوع A, اسکار هیپرتروفیک, تزریق داخل ضایعه}Background And AimHypertrophic scars are highly resistant to the treatment and have a high recurrence rate. Affected patients suffer from aesthetic and functional complications, which may influence their quality of life. Nowadays, various therapeutic modalities have been used in the treatment of hypertrophic scars, but patient's problems remain because of high recurrence rate. This study evaluated the efficacy of intralesional injection of botulinum toxin A in the treatment of hypertrophic scar lesions.MethodsThis randomised controlled trial was performed during 2014 and 2015. Each patient`s lesion was randomly allocated in ine of the two arms of the study: one half of the lesion received monthly 8 IU/cm3 of 200 IU/ml intralesional botulinum toxin A (Dysport, Ipsen Biopharma Ltd., UK) and the other half was injected with the same volume of normal saline. Injections were repeated three times. After 9 months, lesions were evaluated according to Vancouver scar scale.ResultsTwenty-one patients with a mean age of 27.2 years completed the study. In the intervention the mean lesions` pigmentation scale decrease to 0.73, vascularity to 0.9 and pliability to 0.98 (PConclusionIt seems that injection of botulinum toxin A in hypertrophic scar lesions acts as useful adjuvant for other treatment methods.Keywords: botulinum toxin A, hypertrophic scar, intralesional injection} -
Temporomandibular joint (TMJ) ankylosis can restrict the mandibular movement, followed by resulting in numerous problems. To understand the mechanism of TMJ ankylosis (TMJA) and prevent the generation of TMJA is urgent necessary. Although many factors contribute to it, trauma is the most common cause of TMJA. The mechanisms of TMJA are still unclear, and the distraction osteogenesis of the lateral pterygoid muscle (LPM) may play an important role. Injection of very small amounts of botulinum toxin type A (BTA) can temporarily block the muscle’s impulse and has been revealed to be an effective treatment method for many temporomandibular disorders. In this article, we make a hypothesis that LPM injection of BTA as a novel method for immobilization of mandible, followed by preventing the traumatic TMJA. Furthermore, the side effects of local injection of BTA also are minimal, temporary, reversible and self-limiting. If this strategy is validated, LPM injection of BTA will be a cost effective way to be administrated to prevent the traumatic TMJA.Keywords: Botulinum toxin A, Lateral pterygoid muscle, Prevention, Traumatic ankylosis, Temporomandibular joint}
-
مقایسه تاثیر دو روش اسفنکتروتومی داخلی جانبی و تزریق سم بوتولینوم در درمان فیشر آنالزمینه و هدففیشر مزمن آنال یکی از شایع ترین بیماری مقعدی می باشد. بیشتر این بیماران با درمان های نگهدارنده بهبود می-یابند. اما اگر تظاهرات بیمار بیشتر از شش هفته طول بکشد، نوع مزمن می باشد. اسفنکتروتومی به عنوان درمان انتخابی فیشر مزمن آنال شناخته می شود. اما با عوارض بالقوه طولانی مدتی همراه است. بی اختیاری در دفع گاز و مدفوع و عفونت و درد پایدار عوارض ناراحت کننده ای هستند که در 35% بیماران اسفنکتروتومی شده ممکن است حادث شود.مواد و روش هادر یک مطالعه کارآزمایی بالینی تصادفی شده، 86 بیمار مبتلا به فیشر مزمن آنال، به صورت تصادفی به دو گروه تقسیم شدند. بیماران شامل شرایط به دو گروه تقسیم شدند، گروه یک تحت درمان با تزریق 60 واحد سم بوتولینوم در داخل اسفنکتر داخلی معقدی قرار گرفتند و گروه دوم تحت اسنفکتروتومی داخلی جانبی قرار گرفتند و از نظر میزان بهبودی و عوارض بعد از عمل شامل درد و خونریزی و عود و سایر عوارض در طی پیگیری 3 ماهه با یکدیگر مقایسه شدند.یافته هامیزان بهبودی دو هفته پس از درمان برابر با 100% (86 بیمار) بیماران بوده است که از این میان 19 نفر (09/22%) بهبودی نسبی و 67 نفر (91/77%) بهبودی کامل داشته اند. میزان بهبودی کامل در دو گروه مورد مطالعه اسنفکتروتومی داخلی جانبی و تزریق سم بوتولینوم به ترتیب برابر با 72/83% (36 مورد) و 09/72% (31 مورد) بوده است. میزان بهبودی نسبی نیز در دو گروه مذکور به ترتیب (7 مورد) 28/16% و (12 مورد) 91/27% بوده است (194/0=P). در پیگیری 3 ماه پس از درمان؛ میزان بهبودی کامل در دو گروه مورد مطالعه اسنفکتروتومی داخلی جانبی و تزریق سم بوتولینوم به ترتیب برابر با 72/83% (36 مورد) و 09/72% (31 مورد) بوده است. میزان بهبودی نسبی در دو گروه مذکور به ترتیب 3/9% (4 مورد) و 98/6% (3 مورد) بوده است. میزان عود در دو گروه اسنفکتروتومی داخلی جانبی و تزریق سم بوتولینوم نیز به ترتیب 98/6% (3 مورد) و 93/20% (9 مورد) محاسبه شد. تفاوت میان میزان بهبودی و عود 3 ماه پس از درمان در دو گروه مورد مطالعه معنی دار نبوده است (059/0=P). میانگین مدت زمان درد بیماران در گروه تزریق سم بوتولینوم و اسنفکتروتومی داخلی جانبی به ترتیب برابر با 02/2±77/6 و 48/2 ±98/11 روز بدست آمد (001/0>P). میانگین مدت زمان برگشت به کار بیماران به روز در گروه تزریق سم بوتولینوم و اسنفکتروتومی داخلی جانبی به ترتیب برابر با 56/0±51/1 و 66/2±21/9 روز محاسبه شد (001/ 0>P).نتیجه گیریبا توجه به یافته های مطالعه حاضر و نتایج درمانی مشابه در دو گروه اسفنکترتومی داخلی جانبی و تزریق سم بوتولینوم و با در نظر گرفتن طول مدت درد کوتاه تر و مدت زمان بازگشت به کار کمتر، پس از تزریق بوتولینوم، این روش می تواند به عنوان روش جایگزین در درمان فیشر مزمن آنال توصیه گردد. نتیجه گیری قطعی نیاز به انجام مطالعات بیشتر در آینده دارد.
کلید واژگان: فیشر مزمن آنال, اسنفکتروتومی داخلی جانبی, تزریق بوتولینوم}Comparison of Lateral Internal Sphincterotomy and Botulinum Toxin Injection in Treatment of Chronic Anal FissureIntroduction &ObjectiveChronic anal fissure is one of the most common anorectal diseases. Most patients recovered by conservative treatments. But the disease is chronic if clinical manifestations lasts more than six weeks. Sphincterotomy is known as the treatment of choice for chronic anal fissure, although it is associated with long-term potential complications. Flatus and fecal incontinence, infection, and persistent pain are uncomfortable side effects that may occur in 0.35 of patients undergoing sphincterotomy.Materials and MethodsIn a randomized clinical trial, 86 patients with chronic anal fissure were randomly divided into two groups. Eligible patients were divided into two groups: the first group were treated with 60 unit of Dysport injected into the internal anal sphincter, and the second group underwent lateral internal sphincterotomy. Then the rate of recovery and postoperative complications, such as pain, bleeding and recurrence or other complications were compared during the 3-month follow-up.ResultsTwo weeks after the treatment, the recovery rate was 100% (86 patients), from which 19 patients (22.09%) had partial improvement and 67 (77.91%) had complete recovery. The complete recovery rate in the two study groups of PLIS and disport injection were (36 cases) 83.72% and (31 cases) 72.09% respectively. The relative recovery rate in the two groups, were 16.28% and 27.91%, respectively (P=0.194). In 3 months follow-up after the treatment, the complete recovery rate in the two groups of PLIS and disport injection groups were (36 cases) 83.72% and (31 cases) 72.09% respectively. The relative recovery rate in the two groups were respectively (4 cases) 9.3% and (3 cases) 6.98%. The recurrence rate between the two groups of PLIS and disport injection groups were respectively (3 cases) 6.98% and (9 cases) 20.93%. The difference between the recovery rate and recurrence rate, 3 months after the treatment in both groups was not significant (P=0.059). The mean duration of pain for the disport injection and PLIS were respectively 6.77±2.02 and 11.98±2.48 days, (PKeywords: Chronic anal Fissure, Lateral Internal Sphincterotomy, Botulinum Toxin Injection} -
BackgroundBotulinum toxin A (BTA) is a promising therapeutic option in the treatment of allergic rhinitis (AR). Although recent studies have introduced BTA septal injection as an alternative method, the conventional localization for the injection of BTA in patients with AR is still the nasal turbinates. This study was designed to compare the effectiveness and safety of septal BTA injection with turbinal BTA injection in patients with AR.Materials And MethodsThis open-label study was performed on 50 patients with AR who were randomly allocated to septal and turbinal BTA injection groups. All patients received an injection of 40 U of BTA (Dysport®, Ipsen Ltd, Maidenhead, UK) in each side of the nose and were followed for 8 weeks. Prior to the intervention and 8 weeks later, symptom severity and quality of life scores were calculated using the AR symptom severity and Rhinasthma questionnaires respectively.ResultsComparison of pre- and post-treatment symptom severity scores within each group showed a significant reduction of total symptom severity score and severity of sneezing, rhinorrhea, and congestion in both groups (P < 0.05). However, post-treatment symptom severity scores were not significantly different between two groups (P > 0.05). Both methods have improved the quality of life of subjects significantly (P < 0.05). Significantly more patients in the turbinal injection group reported adverse effects (four patient’s vs. one, P < 0.05).ConclusionAlthough both septal and turbinal BTA injections are effective on patients with AR, septal administration of BTA could be safer and easier method. However, further investigations are required to achieve more accurate results.Keywords: Allergic rhinitis, botulinum toxin A, quality of life}
-
BackgroundA variety of techniques for the management of spasticity have been suggested, including positioning, cryotherapy, splinting and casting, biofeedback, electrical stimulation, and medical management by pharmacological agents, Botulinum toxin A (BTA) is now the pharmacological treatment of choice in focal spasticity. BTA by blocking acetylcholine release at neuromuscular junctions accounts for its therapeutic action to relieve spasticity.MethodsA computerized search of Pub Med was carried out to find the latest result about efficacy of BTA in management of post stroke spasticity.ResultAmong 84 articles were found, frothy of them included in this review and divided to lower and upper extremity.ConclusionsBTA is a treatment choice in reducing tone and managing post stroke spasticity.Keywords: Botulinum toxin A, spasticity, stroke}
- نتایج بر اساس تاریخ انتشار مرتب شدهاند.
- کلیدواژه مورد نظر شما تنها در فیلد کلیدواژگان مقالات جستجو شدهاست. به منظور حذف نتایج غیر مرتبط، جستجو تنها در مقالات مجلاتی انجام شده که با مجله ماخذ هم موضوع هستند.
- در صورتی که میخواهید جستجو را در همه موضوعات و با شرایط دیگر تکرار کنید به صفحه جستجوی پیشرفته مجلات مراجعه کنید.